474 related articles for article (PubMed ID: 16677089)
1. Friedreich's ataxia: from disease mechanisms to therapeutic interventions.
Lodi R; Tonon C; Calabrese V; Schapira AH
Antioxid Redox Signal; 2006; 8(3-4):438-43. PubMed ID: 16677089
[TBL] [Abstract][Full Text] [Related]
2. Mitochondrial dysfunction in Friedreich's ataxia: from pathogenesis to treatment perspectives.
Lodi R; Rajagopalan B; Bradley JL; Taylor DJ; Crilley JG; Hart PE; Blamire AM; Manners D; Styles P; Schapira AH; Cooper JM
Free Radic Res; 2002 Apr; 36(4):461-6. PubMed ID: 12069111
[TBL] [Abstract][Full Text] [Related]
3. Mitochondrial dysfunction in friedreich's ataxia.
Lodi R; Taylor DJ; Schapira AH
Biol Signals Recept; 2001; 10(3-4):263-70. PubMed ID: 11351132
[TBL] [Abstract][Full Text] [Related]
4. Friedreich's ataxia and frataxin: molecular genetics, evolution and pathogenesis (Review).
Palau F
Int J Mol Med; 2001 Jun; 7(6):581-9. PubMed ID: 11351269
[TBL] [Abstract][Full Text] [Related]
5. Deferiprone and idebenone rescue frataxin depletion phenotypes in a Drosophila model of Friedreich's ataxia.
Soriano S; Llorens JV; Blanco-Sobero L; Gutiérrez L; Calap-Quintana P; Morales MP; Moltó MD; Martínez-Sebastián MJ
Gene; 2013 Jun; 521(2):274-81. PubMed ID: 23542074
[TBL] [Abstract][Full Text] [Related]
6. Efficient attenuation of Friedreich's ataxia (FRDA) cardiomyopathy by modulation of iron homeostasis-human induced pluripotent stem cell (hiPSC) as a drug screening platform for FRDA.
Lee YK; Lau YM; Ng KM; Lai WH; Ho SL; Tse HF; Siu CW; Ho PW
Int J Cardiol; 2016 Jan; 203():964-71. PubMed ID: 26625322
[TBL] [Abstract][Full Text] [Related]
7. Friedreich ataxia: an update on animal models, frataxin function and therapies.
González-Cabo P; Llorens JV; Palau F; Moltó MD
Adv Exp Med Biol; 2009; 652():247-61. PubMed ID: 20225031
[TBL] [Abstract][Full Text] [Related]
8. Aconitase and mitochondrial iron-sulphur protein deficiency in Friedreich ataxia.
Rötig A; de Lonlay P; Chretien D; Foury F; Koenig M; Sidi D; Munnich A; Rustin P
Nat Genet; 1997 Oct; 17(2):215-7. PubMed ID: 9326946
[TBL] [Abstract][Full Text] [Related]
9. Mitochondrial damage and senescence phenotype of cells derived from a novel frataxin G127V point mutation mouse model of Friedreich's ataxia.
Fil D; Chacko BK; Conley R; Ouyang X; Zhang J; Darley-Usmar VM; Zuberi AR; Lutz CM; Napierala M; Napierala JS
Dis Model Mech; 2020 Jul; 13(7):. PubMed ID: 32586831
[TBL] [Abstract][Full Text] [Related]
10. 'Mitochondrial energy imbalance and lipid peroxidation cause cell death in Friedreich's ataxia'.
Abeti R; Parkinson MH; Hargreaves IP; Angelova PR; Sandi C; Pook MA; Giunti P; Abramov AY
Cell Death Dis; 2016 May; 7(5):e2237. PubMed ID: 27228352
[TBL] [Abstract][Full Text] [Related]
11. Friedreich's ataxia.
Alper G; Narayanan V
Pediatr Neurol; 2003 May; 28(5):335-41. PubMed ID: 12878293
[TBL] [Abstract][Full Text] [Related]
12. Friedreich's ataxia: coenzyme Q10 and vitamin E therapy.
Cooper JM; Schapira AH
Mitochondrion; 2007 Jun; 7 Suppl():S127-35. PubMed ID: 17485244
[TBL] [Abstract][Full Text] [Related]
13. Friedreich's ataxia: past, present and future.
Marmolino D
Brain Res Rev; 2011 Jun; 67(1-2):311-30. PubMed ID: 21550666
[TBL] [Abstract][Full Text] [Related]
14. Friedreich's Ataxia: disease mechanisms, antioxidant and Coenzyme Q10 therapy.
Cooper JM; Schapira AH
Biofactors; 2003; 18(1-4):163-71. PubMed ID: 14695932
[TBL] [Abstract][Full Text] [Related]
15. A novel GAA-repeat-expansion-based mouse model of Friedreich's ataxia.
Anjomani Virmouni S; Ezzatizadeh V; Sandi C; Sandi M; Al-Mahdawi S; Chutake Y; Pook MA
Dis Model Mech; 2015 Mar; 8(3):225-35. PubMed ID: 25681319
[TBL] [Abstract][Full Text] [Related]
16. Targeting lipid peroxidation and mitochondrial imbalance in Friedreich's ataxia.
Abeti R; Uzun E; Renganathan I; Honda T; Pook MA; Giunti P
Pharmacol Res; 2015 Sep; 99():344-50. PubMed ID: 26141703
[TBL] [Abstract][Full Text] [Related]
17. Friedreich's ataxia: clinical aspects and pathogenesis.
Pandolfo M
Semin Neurol; 1999; 19(3):311-21. PubMed ID: 12194387
[TBL] [Abstract][Full Text] [Related]
18. Antioxidant treatment of patients with Friedreich ataxia: four-year follow-up.
Hart PE; Lodi R; Rajagopalan B; Bradley JL; Crilley JG; Turner C; Blamire AM; Manners D; Styles P; Schapira AH; Cooper JM
Arch Neurol; 2005 Apr; 62(4):621-6. PubMed ID: 15824263
[TBL] [Abstract][Full Text] [Related]
19. Deficit of in vivo mitochondrial ATP production in patients with Friedreich ataxia.
Lodi R; Cooper JM; Bradley JL; Manners D; Styles P; Taylor DJ; Schapira AH
Proc Natl Acad Sci U S A; 1999 Sep; 96(20):11492-5. PubMed ID: 10500204
[TBL] [Abstract][Full Text] [Related]
20. Friedreich's Ataxia: from the (GAA)n repeat mediated silencing to new promising molecules for therapy.
Marmolino D; Acquaviva F
Cerebellum; 2009 Sep; 8(3):245-59. PubMed ID: 19165552
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
